

# World Health Organization Model List of Essential Medicines for Children

---

7th List  
2019



World Health  
Organization



# **World Health Organization Model List of Essential Medicines for Children**

**7th List  
2019**

## © World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** World Health Organization Model List of Essential Medicines for Children, 7th List, 2019. Geneva: World Health Organization; 2019. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

The recommendations contained in this publication are based on the advice of independent experts, who have considered the best available evidence, a risk–benefit analysis and other factors, as appropriate. This publication may include recommendations on the use of medicinal products for an indication, in a dosage form, dose regimen, population or other use parameters that are not included in the approved labelling. Relevant stakeholders should familiarize themselves with applicable national legal and ethical requirements. WHO does not accept any liability for the procurement, distribution and/or administration of any product for any use.

7th edition

---

## WHO Model List of Essential Medicines for Children (2019)

### Explanatory notes

---

**This Model List is intended for use for children up to 12 years of age.**

The **core list** presents a list of minimum medicine needs for a basic health-care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.

The **complementary list** presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost–effectiveness in a variety of settings.

The **square box symbol (□)** is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources.

Therapeutic equivalence is indicated only on the basis of reviews of efficacy and safety and when consistent with WHO clinical guidelines. National lists should not use a similar symbol and should be specific in their final selection, which would depend on local availability and price.

The format and numbering of the 21st WHO Model List of Essential Medicines is used for the 7<sup>th</sup> WHO Model Essential List for Children. Some sections have been deleted because they contain medicines that are not relevant for children.

The **a** symbol indicates that there is an age or weight restriction on use of the medicine; details for each medicine are in Table 1.1 of Annex 1.

The presence of an entry on the Essential Medicines List carries no assurance as to pharmaceutical quality. It is the responsibility of the relevant national or regional drug regulatory authority to ensure that each product is of appropriate pharmaceutical quality (including stability) and that when relevant, different products are interchangeable.

For recommendations and advice concerning all aspects of the quality assurance of medicines see the WHO Medicines website [http://www.who.int/medicines/areas/quality\\_safety/quality\\_assurance/en/](http://www.who.int/medicines/areas/quality_safety/quality_assurance/en/).

Medicines and dosage forms are listed in alphabetical order within each section and there is no implication of preference for one form over another. Standard treatment guidelines should be consulted for information on appropriate dosage forms.

The main terms used for dosage forms in the Essential Medicines List can be found in Table 1.2 of Annex 1.

Definitions of many of these terms and pharmaceutical quality requirements applicable to the different categories are published in the current edition of *The International Pharmacopoeia* <http://www.who.int/medicines/publications/pharmacopoeia>.

<b>1. ANAESTHETICS, PREOPERATIVE MEDICINES AND MEDICAL GASES</b>	
<b>1.1 General anaesthetics and oxygen</b>	
<b>1.1.1 Inhalational medicines</b>	
halothane	Inhalation.
isoflurane	Inhalation.
nitrous oxide	Inhalation.
oxygen	Inhalation (medical gas).
<b>1.1.2 Injectable medicines</b>	
ketamine	Injection: 50 mg (as hydrochloride)/mL in 10-mL vial.
propofol *	Injection: 10 mg/mL; 20 mg/mL. * Thiopental may be used as an alternative depending on local availability and cost.
<b>1.2 Local anaesthetics</b>	
<input type="checkbox"/> bupivacaine	Injection: 0.25%; 0.5% (hydrochloride) in vial. Injection for spinal anaesthesia: 0.5% (hydrochloride) in 4-mL ampoule to be mixed with 7.5% glucose solution.
<input type="checkbox"/> lidocaine	Injection: 1%; 2% (hydrochloride) in vial. Injection for spinal anaesthesia: 5% (hydrochloride) in 2-mL ampoule to be mixed with 7.5% glucose solution. Topical forms: 2% to 4% (hydrochloride).
lidocaine + epinephrine (adrenaline)	Dental cartridge: 2% (hydrochloride) + epinephrine 1:80 000. Injection: 1%; 2% (hydrochloride or sulfate) + epinephrine 1:200 000 in vial.
<b>1.3 Preoperative medication and sedation for short-term procedures</b>	
atropine	Injection: 1 mg (sulfate) in 1-mL ampoule.
<input type="checkbox"/> midazolam	Injection: 1 mg/mL. Oral liquid: 2 mg/mL. Tablet: 7.5 mg; 15 mg.
morphine	Injection: 10 mg (sulfate or hydrochloride) in 1-mL ampoule.
<b>1.4 Medical gases</b>	
oxygen*	Inhalation For use in the management of hypoxaemia. *No more than 30% oxygen should be used to initiate resuscitation of neonates less than or equal to 32 weeks of gestation.
<b>2. MEDICINES FOR PAIN AND PALLIATIVE CARE</b>	
<b>2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)</b>	

ibuprofen <input type="checkbox"/> a	<p><b>Oral liquid:</b> 200 mg/5 mL.</p> <p><b>Tablet:</b> 200 mg; 400 mg; 600 mg.</p> <p><input type="checkbox"/> a Not in children less than 3 months.</p>
paracetamol*	<p><b>Oral liquid:</b> 120 mg/5 mL; 125 mg/5 mL.</p> <p><b>Suppository:</b> 100 mg.</p> <p><b>Tablet:</b> 100 mg to 500 mg.</p> <p>* Not recommended for anti-inflammatory use due to lack of proven benefit to that effect.</p>
<b>2.2 Opioid analgesics</b>	
<input type="checkbox"/> morphine*	<p><b>Granules (slow release; to mix with water):</b> 20 mg to 200 mg (morphine sulfate).</p> <p><b>Injection:</b> 10 mg (morphine hydrochloride or morphine sulfate) in 1-mL ampoule.</p> <p><b>Oral liquid:</b> 10 mg (morphine hydrochloride or morphine sulfate)/5 mL.</p> <p><b>Tablet (slow release):</b> 10 mg – 200mg (morphine hydrochloride or morphine sulfate).</p> <p><b>Tablet (immediate release):</b> 10 mg (morphine sulfate).</p> <p>*Alternatives limited to hydromorphone and oxycodone.</p>
<i>Complementary list</i>	
methadone*	<p><b>Tablet:</b> 5 mg; 10 mg (as hydrochloride).</p> <p><b>Oral liquid:</b> 5mg/ 5mL; 10mg/ 5mL (as hydrochloride).</p> <p><b>Concentrate for oral liquid:</b> 5 mg/ mL; 10mg/ mL (as hydrochloride)</p> <p>*For the management of cancer pain.</p>
<b>2.3 Medicines for other symptoms common in palliative care</b>	
amitriptyline	<b>Tablet:</b> 10 mg; 25 mg.
cyclizine	<b>Injection:</b> 50 mg/mL. <b>Tablet:</b> 50 mg.
dexamethasone	<b>Injection:</b> 4 mg/mL in 1-mL ampoule (as disodium phosphate salt). <b>Oral liquid:</b> 2 mg/5 mL. <b>Tablet:</b> 2 mg.
diazepam	<b>Injection:</b> 5 mg/mL. <b>Oral liquid:</b> 2 mg/5 mL. <b>Rectal solution:</b> 2.5 mg; 5 mg; 10 mg. <b>Tablet:</b> 5 mg; 10 mg.
docusate sodium	<b>Capsule:</b> 100 mg. <b>Oral liquid:</b> 50 mg/5 mL.
fluoxetine <input type="checkbox"/> a	<b>Solid oral dosage form:</b> 20 mg (as hydrochloride). <input type="checkbox"/> a >8 years.

hyoscine hydrobromide	<b>Injection:</b> 400 micrograms/mL; 600 micrograms/mL. <b>Transdermal patches:</b> 1 mg/72 hours.
lactulose	<b>Oral liquid:</b> 3.1–3.7 g/5 mL.
midazolam	<b>Injection:</b> 1 mg/mL; 5 mg/mL. <b>Oral liquid:</b> 2mg/mL. <b>Solid oral dosage form:</b> 7.5 mg; 15 mg.
<input type="checkbox"/> ondansetron <sup>a</sup>	<b>Injection:</b> 2 mg base/mL in 2-mL ampoule (as hydrochloride). <b>Oral liquid:</b> 4 mg base/5 mL. <b>Solid oral dosage form:</b> Eq 4 mg base; Eq 8 mg base. <sup>a</sup> >1 month.
senna	<b>Oral liquid:</b> 7.5 mg/5 mL.
<b>3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS</b>	
dexamethasone	<b>Injection:</b> 4 mg/mL in 1-mL ampoule (as disodium phosphate salt).
epinephrine (adrenaline)	<b>Injection:</b> 1 mg (as hydrochloride <b>or</b> hydrogen tartrate) in 1-mL ampoule.
hydrocortisone	<b>Powder for injection:</b> 100 mg (as sodium succinate) in vial.
<input type="checkbox"/> loratadine *	<b>Oral liquid:</b> 1 mg/mL. <b>Tablet:</b> 10 mg. *There may be a role for sedating antihistamines for limited indications.
<input type="checkbox"/> prednisolone	<b>Oral liquid:</b> 5 mg/mL. <b>Tablet:</b> 5 mg; 25 mg.
<b>4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS</b>	
<b>4.1 Non-specific</b>	
charcoal, activated	<b>Powder.</b>
<b>4.2 Specific</b>	
acetylcysteine	<b>Injection:</b> 200 mg/mL in 10-mL ampoule. <b>Oral liquid:</b> 10%; 20%.
atropine	<b>Injection:</b> 1 mg (sulfate) in 1-mL ampoule.
calcium gluconate	<b>Injection:</b> 100 mg/mL in 10-mL ampoule.
naloxone	<b>Injection:</b> 400 micrograms (hydrochloride) in 1-mL ampoule.
<b>Complementary List</b>	
<i>deferoxamine</i>	<b>Powder for injection:</b> 500 mg (mesilate) in vial.
<i>dimercaprol</i>	<b>Injection in oil:</b> 50 mg/mL in 2-mL ampoule.
<i>fomepizole</i>	<b>Injection:</b> 5 mg/mL (sulfate) in 20-mL ampoule or 1 g/mL (base) in 1.5-mL ampoule.
<i>sodium calcium edetate</i>	<b>Injection:</b> 200 mg/mL in 5-mL ampoule.



<i>succimer</i>	<b>Solid oral dosage form:</b> 100 mg.
<b>5. ANTICONVULSANTS/ANTIEPILEPTICS</b>	
carbamazepine	<b>Oral liquid:</b> 100 mg/5 mL. <b>Tablet (chewable):</b> 100 mg; 200 mg. <b>Tablet (scored):</b> 100 mg; 200 mg.
diazepam	<b>Gel or rectal solution:</b> 5 mg/mL in 0.5 mL; 2-mL; 4-mL tubes.
lamotrigine*	<b>Tablet:</b> 25 mg; 50 mg; 100 mg; 200 mg. <b>Tablet (chewable, dispersible):</b> 2 mg; 5 mg; 25 mg; 50 mg; 100 mg; 200 mg. *as adjunctive therapy for treatment-resistant partial or generalized seizures.
<input type="checkbox"/> lorazepam	<b>Parenteral formulation:</b> 2 mg/mL in 1-mL ampoule; 4 mg/mL in 1-mL ampoule.
midazolam	<b>Solution for oromucosal administration:</b> 5 mg/mL; 10 mg/mL <b>Ampoule*:</b> 1 mg/ mL; 10 mg/mL *for buccal administration when solution for oromucosal administration is not available
phenobarbital	<b>Injection:</b> 200 mg/mL (sodium). <b>Oral liquid:</b> 15 mg/5 mL. <b>Tablet:</b> 15 mg to 100 mg.
phenytoin	<b>Injection:</b> 50 mg/mL in 5-mL vial (sodium salt). <b>Oral liquid:</b> 25 mg to 30 mg/5 mL.* <b>Solid oral dosage form:</b> 25 mg; 50 mg; 100 mg (sodium salt). <b>Tablet (chewable):</b> 50 mg. * The presence of both 25 mg/5 mL and 30 mg/5 mL strengths on the same market would cause confusion in prescribing and dispensing and should be avoided.
valproic acid (sodium valproate)	<b>Oral liquid:</b> 200 mg/5 mL. <b>Tablet (crushable):</b> 100 mg. <b>Tablet (enteric-coated):</b> 200 mg; 500 mg (sodium valproate).
<b>Complementary List</b>	
<i>ethosuximide</i>	<b>Capsule:</b> 250 mg. <b>Oral liquid:</b> 250 mg/5 mL.
<i>valproic acid (sodium valproate)</i>	<b>Injection:</b> 100 mg/ mL in 4- mL ampoule; 100 mg/ mL in 10- mL ampoule.
<b>6. ANTI-INFECTIVE MEDICINES</b>	
<b>6.1 Anthelmintics</b>	
<b>6.1.1 Intestinal anthelmintics</b>	
albendazole	<b>Tablet (chewable):</b> 400 mg.
ivermectin	<b>Tablet (scored):</b> 3 mg.

levamisole	Tablet: 50 mg; 150 mg (as hydrochloride).
mebendazole	Tablet (chewable): 100 mg; 500 mg.
niclosamide	Tablet (chewable): 500 mg.
praziquantel	Tablet: 150 mg; 600 mg.
pyrantel	Oral liquid: 50 mg (as embonate or pamoate)/mL. Tablet (chewable): 250 mg (as embonate or pamoate).
<b>6.1.2 Antifilarials</b>	
albendazole	Tablet (chewable): 400 mg.
diethylcarbamazine	Tablet: 50 mg; 100 mg (dihydrogen citrate).
ivermectin	Tablet (scored): 3 mg.
<b>6.1.3 Antischistosomes and other antitremitode medicines</b>	
praziquantel	Tablet: 600 mg.
triclabendazole	Tablet: 250 mg.
<b>Complementary List</b>	
oxamniquine*	Capsule: 250 mg. Oral liquid: 250 mg/5 mL. * Oxamniquine is listed for use when praziquantel treatment fails.

## 6.2 Antibacterials

To assist in the development of tools for antibiotic stewardship at local, national and global levels and to reduce antimicrobial resistance, the Access, Watch, Reserve (AWaRe) classification of antibiotics was developed – where antibiotics are classified into different groups to emphasize the importance of their appropriate use.

### ACCESS GROUP ANTIBIOTICS

This group includes antibiotics that have activity against a wide range of commonly encountered susceptible pathogens while also showing lower resistance potential than antibiotics in the other groups. Selected Access group antibiotics are recommended as essential first or second choice empiric treatment options for infectious syndromes reviewed by the EML Expert Committee and are listed as individual medicines on the Model Lists to improve access and promote appropriate use. They are essential antibiotics that should be widely available, affordable and quality assured.

### WATCH GROUP ANTIBIOTICS

This group includes antibiotic classes that have higher resistance potential and includes most of the highest priority agents among the Critically Important Antimicrobials for Human Medicine<sup>1</sup> and/or antibiotics that are at relatively high risk of selection of bacterial resistance. These medicines should be prioritized as key targets of stewardship programs and monitoring. Selected Watch group antibiotics are recommended as essential first or second choice empiric treatment options for a limited number of specific infectious syndromes and are listed as individual medicines on the Model Lists.

<sup>1</sup> <http://apps.who.int/iris/bitstream/10665/251715/1/9789241511469-eng.pdf?ua=1>

### RESERVE GROUP ANTIBIOTICS

This group includes antibiotics and antibiotic classes that should be reserved for treatment of confirmed or suspected infections due to multi-drug-resistant organisms. Reserve group antibiotics should be treated as “last resort” options. Selected Reserve group antibiotics are listed as individual medicines on the Model Lists when they have a favourable risk-benefit profile and proven activity against “Critical Priority” or “High Priority” pathogens identified by the WHO Priority Pathogens List<sup>1</sup>, notably carbapenem resistant *Enterobacteriaceae*. These antibiotics should be accessible, but their use should be tailored to highly specific patients and settings, when all alternatives have failed or are not suitable. These medicines could be protected and prioritized as key targets of national and international stewardship programs involving monitoring and utilization reporting, to preserve their effectiveness.

<sup>1</sup> [https://www.who.int/medicines/areas/rational\\_use/PPLreport\\_2017\\_09\\_19.pdf?ua=1](https://www.who.int/medicines/areas/rational_use/PPLreport_2017_09_19.pdf?ua=1)

6.2.1 Access group antibiotics		
amikacin	Injection: 250 mg (as sulfate)/mL in 2- mL vial	
	<b>FIRST CHOICE</b> - <i>pyelonephritis (severe)</i> - <i>high-risk febrile neutropenia</i>	<b>SECOND CHOICE</b> - <i>sepsis in neonates and children</i>
amoxicillin	Powder for oral liquid: 125 mg (as trihydrate)/5 mL; 250 mg (as trihydrate)/5 mL . Solid oral dosage form: 250 mg; 500 mg (as trihydrate). Powder for injection: 250 mg; 500 mg; 1 g (as sodium) in vial.	
	<b>FIRST CHOICE</b> - <i>community acquired pneumonia (mild to moderate)</i> - <i>community acquired pneumonia (severe)</i> - <i>complicated severe acute malnutrition</i> - <i>lower urinary tract infections</i> - <i>otitis media</i> - <i>pharyngitis</i> - <i>sepsis in neonates and children</i> - <i>sinusitis</i> - <i>uncomplicated severe acute malnutrition</i> - <i>progressive apical dental abscess</i>	<b>SECOND CHOICE</b> - <i>acute bacterial meningitis</i>
amoxicillin + clavulanic acid	Oral liquid: 125 mg amoxicillin + 31.25 mg clavulanic acid/5 mL AND 250 mg amoxicillin + 62.5 mg clavulanic acid/5 mL . Tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt). Powder for injection: 500 mg (as sodium) + 100 mg (as potassium salt); 1000 mg (as sodium) + 200 mg (as potassium salt) in vial.	
	<b>FIRST CHOICE</b> - <i>community acquired pneumonia (severe)</i> - <i>complicated intraabdominal infections (mild to moderate)</i> - <i>hospital acquired pneumonia</i> - <i>low-risk febrile neutropenia</i> - <i>lower urinary tract infections</i> - <i>sinusitis</i> - <i>skin and soft tissue infections</i>	<b>SECOND CHOICE</b> - <i>bone and joint infections</i> - <i>community acquired pneumonia (mild to moderate)</i> - <i>community acquired pneumonia (severe)</i> - <i>otitis media</i> - <i>surgical prophylaxis</i>
ampicillin	Powder for injection: 500 mg; 1 g (as sodium salt) in vial.	
	<b>FIRST CHOICE</b> - <i>community acquired pneumonia (severe)</i> - <i>complicated severe acute malnutrition</i> - <i>sepsis in neonates and children</i>	<b>SECOND CHOICE</b> - <i>acute bacterial meningitis</i>

benzathine benzylpenicillin	<b>Powder for injection:</b> 900 mg benzylpenicillin (= 1.2 million IU) in 5- mL vial; 1.44 g benzylpenicillin (= 2.4 million IU) in 5- mL vial.	
	<b>FIRST CHOICE</b> - <i>syphilis (congenital)</i>	<b>SECOND CHOICE</b>
benzylpenicillin	<b>Powder for injection:</b> 600 mg (= 1 million IU); 3 g (= 5 million IU) (sodium or potassium salt) in vial.	
	<b>FIRST CHOICE</b> - <i>community acquired pneumonia (severe)</i> - <i>complicated severe acute malnutrition</i> - <i>sepsis in neonates and children</i> - <i>syphilis (congenital)</i>	<b>SECOND CHOICE</b> - <i>acute bacterial meningitis</i>
cefalexin	<b>Powder for reconstitution with water:</b> 125 mg/5 mL; 250 mg/5 mL (anhydrous). <b>Solid oral dosage form:</b> 250 mg (as monohydrate).	
	<b>FIRST CHOICE</b>	<b>SECOND CHOICE</b> - <i>pharyngitis</i> - <i>skin and soft tissue infections</i>
cefazolin <sup>a</sup>	<b>Powder for injection:</b> 1 g (as sodium salt) in vial. <sup>a</sup> >1 month.	
	<b>FIRST CHOICE</b> - <i>surgical prophylaxis</i>	<b>SECOND CHOICE</b> - <i>bone and joint infections</i>
chloramphenicol	<b>Capsule:</b> 250 mg. <b>Oily suspension for injection*:</b> 0.5 g (as sodium succinate)/ mL in 2- mL ampoule. * Only for the presumptive treatment of epidemic meningitis in children older than 2 years. <b>Oral liquid:</b> 150 mg (as palmitate)/5 mL. <b>Powder for injection:</b> 1 g (sodium succinate) in vial.	
	<b>FIRST CHOICE</b>	<b>SECOND CHOICE</b> - <i>acute bacterial meningitis</i>
clindamycin	<b>Capsule:</b> 150 mg (as hydrochloride). <b>Injection:</b> 150 mg (as phosphate)/ mL. <b>Oral liquid:</b> 75 mg/5 mL (as palmitate) .	
	<b>FIRST CHOICE</b>	<b>SECOND CHOICE</b> - <i>bone and joint infections</i>

□ cloxacillin*	<p><b>Capsule:</b> 500 mg; 1 g (as sodium salt).</p> <p><b>Powder for injection:</b> 500 mg (as sodium salt) in vial.</p> <p><b>Powder for oral liquid:</b> 125 mg (as sodium salt)/5 mL.</p> <p>*cloxacillin, dicloxacillin and flucloxacillin are preferred for oral administration due to better bioavailability.</p>	
	<p><b>FIRST CHOICE</b></p> <p>- bone and joint infections - skin and soft tissue infections</p>	<p><b>SECOND CHOICE</b></p> <p>- sepsis in neonates and children</p>
doxycycline <b>a</b>	<p><b>Oral liquid:</b> 25 mg/5 mL ; 50 mg/5 mL (anhydrous) .</p> <p><b>Solid oral dosage form:</b> 50 mg ; 100 mg (as hyclate).</p> <p><b>Powder for injection:</b> 100 mg in vial</p> <p><b>a</b> Use in children &lt;8 years only for life-threatening infections when no alternative exists.</p>	
	<p><b>FIRST CHOICE</b></p>	<p><b>SECOND CHOICE</b></p> <p>- cholera - community acquired pneumonia (mild to moderate)</p>
gentamicin	<p><b>Injection:</b> 10 mg; 40 mg (as sulfate)/ mL in 2- mL vial.</p>	
	<p><b>FIRST CHOICE</b></p> <p>- community acquired pneumonia (severe) - complicated severe acute malnutrition - sepsis in neonates and children</p>	<p><b>SECOND CHOICE</b></p> <p>- surgical prophylaxis</p>
metronidazole	<p><b>Injection:</b> 500 mg in 100- mL vial.</p> <p><b>Oral liquid:</b> 200 mg (as benzoate)/5 mL.</p> <p><b>Tablet:</b> 200 mg to 500 mg.</p>	
	<p><b>FIRST CHOICE</b></p> <p>- <i>C. difficile</i> infection - complicated intra-abdominal infections (mild to moderate) - complicated intra-abdominal infections (severe) - surgical prophylaxis</p>	<p><b>SECOND CHOICE</b></p> <p>- complicated intra-abdominal infections (mild to moderate)</p>
nitrofurantoin	<p><b>Oral liquid:</b> 25 mg/5 mL.</p> <p><b>Tablet:</b> 100 mg.</p>	
	<p><b>FIRST CHOICE</b></p> <p>- lower urinary tract infections</p>	<p><b>SECOND CHOICE</b></p>
phenoxymethylpenicillin	<p><b>Powder for oral liquid:</b> 250 mg (as potassium salt)/5 mL.</p> <p><b>Tablet:</b> 250 mg (as potassium salt).</p>	

	<b>FIRST CHOICE</b> - <i>community acquired pneumonia (mild to moderate)</i> - <i>pharyngitis</i> - <i>progressive apical dental abscess</i>	<b>SECOND CHOICE</b>
procaine benzylpenicillin*	<b>Powder for injection:</b> 1 g (=1 million IU); 3 g (=3 million IU) in vial. * Procaine benzylpenicillin is not recommended as first-line treatment for neonatal sepsis / sepsis except in settings with high neonatal mortality, when given by trained health workers in cases where hospital care is not achievable.	
	<b>FIRST CHOICE</b> - <i>syphilis (congenital)</i>	<b>SECOND CHOICE</b>
sulfamethoxazole + trimethoprim*	<b>Injection:</b> 80 mg + 16 mg/ mL in 5- mL ampoule; 80 mg + 16 mg/ mL in 10- mL ampoule. <b>Oral liquid:</b> 200 mg + 40 mg/5 mL. <b>Tablet:</b> 100 mg + 20 mg; 400 mg + 80 mg *single agent trimethoprim may be an alternative for lower urinary tract infection.	
	<b>FIRST CHOICE</b> - <i>lower urinary tract infections</i>	<b>SECOND CHOICE</b> - <i>acute invasive bacterial diarrhoea / dysentery</i>
	<b>6.2.2 Watch group antibiotics</b>	
azithromycin*	<b>Capsule:</b> 250 mg; 500 mg (anhydrous). <b>Oral liquid:</b> 200 mg/5 mL. * also listed for single-dose treatment of trachoma and yaws.	
	<b>FIRST CHOICE</b> - <i>cholera</i> - <i>enteric fever</i>	<b>SECOND CHOICE</b> - <i>acute invasive bacterial diarrhoea / dysentery</i>
cefixime	<b>Capsules or tablets:</b> 200 mg; 400 mg (as trihydrate) <b>Powder for oral liquid:</b> 100 mg /5 mL	
	<b>FIRST CHOICE</b>	<b>SECOND CHOICE</b> - <i>acute invasive bacterial diarrhoea / dysentery</i>

cefotaxime*	<b>Powder for injection:</b> 250 mg per vial (as sodium salt) * 3rd generation cephalosporin of choice for use in hospitalized neonates.	
	<b>FIRST CHOICE</b> - acute bacterial meningitis - community acquired pneumonia (severe) - complicated intraabdominal infections (mild to moderate) - complicated intrabdominal infections (severe) - hospital acquired pneumonia - pyelonephritis (severe)	<b>SECOND CHOICE</b> - bone and joint infections - pyelonephritis (mild to moderate) - sepsis in neonates and children
ceftriaxone* <b>a</b>	<b>Powder for injection:</b> 250 mg; 1 g (as sodium salt) in vial. * Do not administer with calcium and avoid in infants with hyperbilirubinaemia. <b>a</b> >41 weeks corrected gestational age.	
	<b>FIRST CHOICE</b> - acute bacterial meningitis - community acquired pneumonia (severe) - complicated intraabdominal infections (mild to moderate) - complicated intraabdominal infections (severe) - hospital acquired pneumonia - pyelonephritis (severe) - enteric fever	<b>SECOND CHOICE</b> - acute invasive bacterial diarrhoea / dysentery - bone and joint infections - pyelohepnritis or prostatitis (mild to moderate) - sepsis in neonates and children
cefuroxime	<b>Powder for injection:</b> 250 mg, 750 mg, 1.5 g (as sodium salt) in vial	
	<b>FIRST CHOICE</b>	<b>SECOND CHOICE</b> - surgical prophylaxis
ciprofloxacin	<b>Oral liquid:</b> 250 mg/5 mL (anhydrous) . <b>Solution for IV infusion:</b> 2 mg/ mL (as hyclate) . <b>Tablet:</b> 250 mg (as hydrochloride).	
	<b>FIRST CHOICE</b> - acute invasive bacterial diarrhoea / dysentery - low-risk febrile neutropenia - pyelonephritis (mild to moderate) - enteric fever	<b>SECOND CHOICE</b> - cholera - complicated intraabdominal infections (mild to moderate)
clarithromycin*	<b>Solid oral dosage form:</b> 500 mg. <b>Powder for oral liquid:</b> 125 mg/5 mL; 250 mg/5 mL <b>Powder for injection:</b> 500 mg in vial *erythromycin may be an alternative	



	FIRST CHOICE	SECOND CHOICE - <i>pharyngitis</i>
piperacillin + tazobactam	Powder for injection: 2 g (as sodium salt) + 250 mg (as sodium salt); 4 g (as sodium salt) + 500 mg (as sodium salt) in vial	
	FIRST CHOICE - <i>complicated intraabdominal infections (severe)</i> - <i>high-risk febrile neutropenia</i> - <i>hospital acquired pneumonia</i>	SECOND CHOICE
vancomycin	Capsule: 125 mg; 250 mg (as hydrochloride).	
		SECOND CHOICE - <i>C. difficile infection</i>
<b>Complementary List</b>		
<i>ceftazidime</i>	Powder for injection: 250 mg or 1 g (as pentahydrate) in vial.	
<i>meropenem*</i> <sup>a</sup>	Powder for injection: 500 mg (as trihydrate); 1 g (as trihydrate) in vial <sup>a</sup> >3 months. * <i>imipenem + cilastatin</i> is an alternative except for acute bacterial meningitis where <i>meropenem</i> is preferred.	
	FIRST CHOICE	SECOND CHOICE - <i>acute bacterial meningitis in neonates</i> - <i>complicated intraabdominal infections (severe)</i> - <i>high-risk febrile neutropenia</i>
<i>vancomycin</i>	Powder for injection: 250 mg (as hydrochloride) in vial.	
	FIRST CHOICE	SECOND CHOICE - <i>high-risk febrile neutropenia</i>
<b>6.2.3 Reserve group antibiotics</b>		
<b>Complementary List</b>		
<i>ceftazidime + avibactam</i>	Powder for injection: 2 g + 0.5 g in vial	
<i>colistin</i>	Powder for injection: 1 million I.U. (as colisthemethate sodium) in vial	
<i>fosfomycin</i>	Powder for injection: 2 g; 4 g (as sodium) in vial	
<i>linezolid</i>	Injection for intravenous administration: 2 mg/ mL in 300 mL bag.	
	Powder for oral liquid: 100 mg/5 mL.	
	Tablet: 400 mg; 600 mg.	
<i>polymyxin B</i>	Powder for injection: 500,000 I.U. in vial	

<b>6.2.4 Antileprosy medicines</b>	
Medicines used in the treatment of leprosy should never be used except in combination. Combination therapy is essential to prevent the emergence of drug resistance. Colour-coded blister packs (MDT blister packs) containing standard two-medicine (paucibacillary leprosy) or three-medicine (multibacillary leprosy) combinations for adult and childhood leprosy should be used. MDT blister packs can be supplied free of charge through WHO.	
clofazimine	<b>Capsule:</b> 50 mg; 100 mg.
dapsone	<b>Tablet:</b> 25 mg; 50 mg; 100 mg.
rifampicin	<b>Solid oral dosage form:</b> 150 mg; 300 mg.
<b>6.2.5 Antituberculosis medicines</b>	
WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.	
ethambutol	<b>Oral liquid:</b> 25 mg/mL. <b>Tablet:</b> 100 mg; 400 mg (hydrochloride). <b>Tablet (dispersible):</b> 100 mg
isoniazid	<b>Oral liquid:</b> 50 mg/5 mL. <b>Tablet:</b> 100 mg to 300 mg. <b>Tablet (scored):</b> 50 mg. <b>Tablet (dispersible):</b> 100 mg
isoniazid + pyrazinamide + rifampicin	<b>Tablet (dispersible):</b> 50 mg + 150 mg + 75 mg.
isoniazid + rifampicin	<b>Tablet (dispersible):</b> 50 mg + 75 mg.
pyrazinamide	<b>Oral liquid:</b> 30 mg/mL. <b>Tablet:</b> 400 mg. <b>Tablet (dispersible):</b> 150 mg. <b>Tablet (scored):</b> 150 mg.
rifampicin	<b>Oral liquid:</b> 20 mg/mL. <b>Solid oral dosage form:</b> 150 mg; 300 mg.
rifapentine*	<b>Tablet:</b> 150 mg *For treatment of latent TB infection (LTBI) only
<b>Complementary List</b>	
<b>Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.</b>	
amikacin	<b>Powder for injection:</b> 100 mg; 500 mg; 1 g (as sulfate) in vial.
amoxicillin + clavulanic acid*	<b>Oral liquid:</b> 125 mg amoxicillin + 31.25 mg clavulanic acid/5 mL; 250 mg amoxicillin + 62.5 mg clavulanic acid/5 mL. <b>Tablet:</b> 500 mg (as trihydrate) + 125 mg (as potassium salt). *for use only in combination with meropenem
bedaquiline <sup>a</sup>	<b>Tablet:</b> 100 mg <sup>a</sup> ≥ 6 years
clofazimine	<b>Solid oral dosage form:</b> 50 mg; 100 mg

<i>cycloserine</i>	<b>Solid oral dosage form:</b> 125 mg; 250 mg
<i>delamanid</i> <sup>a</sup>	<b>Tablet:</b> 50 mg <sup>a</sup> ≥6 years
<i>ethionamide</i> *	<b>Tablet:</b> 125 mg; 250 mg <b>Tablet (dispersible):</b> 125 mg *Protionamide may be used as an alternative.
<i>levofloxacin</i>	<b>Tablet:</b> 250 mg; 500 mg <b>Tablet (dispersible):</b> 100 mg
<i>linezolid</i>	<b>Injection for intravenous administration:</b> 2 mg/mL in 300 mL bag <b>Powder for oral liquid:</b> 100 mg/5 mL <b>Tablet:</b> 400 mg; 600 mg <b>Tablet (dispersible):</b> 150 mg
<i>meropenem</i>	<b>Powder for injection:</b> 500 mg (as trihydrate); 1 g (as trihydrate) in vial
<i>moxifloxacin</i>	<b>Tablet:</b> 400 mg <b>Tablet (dispersible):</b> 100 mg
<i>p-aminosalicylic acid</i>	<b>Granules:</b> 4 g in sachet. <b>Tablet:</b> 500 mg.
<i>streptomycin</i>	<b>Powder for injection:</b> 1 g (as sulfate) in vial.
<b>6.3 Antifungal medicines</b>	
amphotericin B	<b>Powder for injection:</b> 50 mg in vial (as sodium deoxycholate or liposomal complex).
fluconazole	<b>Capsule:</b> 50 mg. <b>Injection:</b> 2 mg/mL in vial. <b>Oral liquid:</b> 50 mg/5 mL.
flucytosine	<b>Capsule:</b> 250 mg. <b>Infusion:</b> 2.5 g in 250 mL.
griseofulvin	<b>Oral liquid:</b> 125 mg/5 mL. <b>Solid oral dosage form:</b> 125 mg; 250 mg.
itraconazole*	<b>Capsule:</b> 100 mg. <b>Oral liquid:</b> 10 mg/mL. *For treatment of chronic pulmonary aspergillosis, acute invasive aspergillosis, histoplasmosis, sporotrichosis, paracoccidioidomycosis, mycoses caused by <i>T. marneffe</i> and chromoblastomycosis; and prophylaxis of histoplasmosis and infections caused by <i>T. marneffe</i> in AIDS patients.
nystatin	<b>Lozenge:</b> 100 000 IU. <b>Oral liquid:</b> 50 mg/5 mL; 100 000 IU/mL. <b>Tablet:</b> 100 000 IU; 500 000 IU.

voriconazole*	<p><b>Tablet:</b> 50 mg; 200 mg.</p> <p><b>Powder for injection:</b> 200 mg in vial.</p> <p><b>Powder for oral liquid:</b> 40 mg/mL.</p> <p>* For treatment of chronic pulmonary aspergillosis and acute invasive aspergillosis.</p>
<b>Complementary List</b>	
potassium iodide	<b>Saturated solution.</b>
<b>6.4 Antiviral medicines</b>	
<b>6.4.1 Antih herpes medicines</b>	
aciclovir	<p><b>Oral liquid:</b> 200 mg/5 mL.</p> <p><b>Powder for injection:</b> 250 mg (as sodium salt) in vial.</p> <p><b>Tablet:</b> 200 mg.</p>
<b>6.4.2 Antiretrovirals</b>	
<p>Based on current evidence and experience of use, medicines in the following classes of antiretrovirals are included as essential medicines for treatment and prevention of HIV (prevention of mother-to-child transmission and post-exposure prophylaxis). WHO emphasizes the importance of using these products in accordance with global and national guidelines. WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.</p> <p>Scored tablets can be used in children and therefore can be considered for inclusion in the listing of tablets, provided that adequate quality products are available.</p>	
<b>6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors</b>	
abacavir (ABC)	<b>Tablet (dispersible, scored):</b> 60 mg (as sulfate).
lamivudine (3TC)	<p><b>Oral liquid:</b> 50 mg/5 mL.</p> <p><b>Tablet:</b> 150 mg.</p>
zidovudine (ZDV or AZT)	<b>Oral liquid:</b> 50 mg/5 mL.
<b>6.4.2.2 Non-nucleoside reverse transcriptase inhibitors</b>	
efavirenz (EFV or EFZ) <sup>a</sup>	<p><b>Tablet:</b> 200 mg (scored).</p> <p><sup>a</sup> &gt;3 years or &gt;10 kg weight.</p>
nevirapine (NVP) <sup>a</sup>	<p><b>Oral liquid:</b> 50 mg/5 mL.</p> <p><b>Tablet:</b> 50 mg (dispersible).</p> <p><sup>a</sup> &gt; 6 weeks</p>
<b>6.4.2.3 Protease inhibitors</b>	
<p>Selection of protease inhibitor(s) from the Model List will need to be determined by each country after consideration of international and national treatment guidelines and experience. Ritonavir is recommended for use in combination as a pharmacological booster, and not as an antiretroviral in its own right. All other protease inhibitors should be used in boosted forms (e.g. with ritonavir).</p>	
atazanavir <sup>a</sup>	<p><b>Solid oral dosage form:</b> 100 mg; (as sulfate).</p> <p><sup>a</sup> &gt;25 kg.</p>
darunavir <sup>a</sup>	<p><b>Tablet:</b> 75 mg.</p> <p><sup>a</sup> &gt;3 years</p>

lopinavir + ritonavir (LPV/r)	<p>Oral liquid: 400 mg + 100 mg/5 mL.</p> <p>Tablet (heat stable): 100 mg + 25 mg-</p> <p>Solid oral dosage form: 40 mg + 10 mg</p>
ritonavir	<p>Oral liquid: 400 mg/5 mL.</p> <p>Tablet (heat stable): 25 mg; 100 mg.</p> <p>Oral powder: 100 mg in sachet</p>
<b>6.4.2.4 Integrase inhibitors</b>	
dolutegravir <sup>a</sup>	<p>Tablet: 50 mg</p> <p><sup>a</sup> ≥ 25 kg</p>
raltegravir*	<p>Tablet (chewable): 25 mg; 100 mg.</p> <p>Tablet: 400 mg.</p> <p>Granules for oral suspension: 100 mg in sachet</p> <p>*for use in second-line regimens in accordance with WHO treatment guidelines</p>
<b>FIXED-DOSE COMBINATIONS</b>	
abacavir + lamivudine	Tablet (dispersible, scored): 120 mg (as sulfate) + 60 mg.
lamivudine + nevirapine + zidovudine	Tablet: 30 mg + 50 mg + 60 mg.
lamivudine + zidovudine	Tablet: 30 mg + 60 mg.
<b>6.4.2.5 Medicines for prevention of HIV-related opportunistic infections</b>	
isoniazid + pyridoxine + sulfamethoxazole + trimethoprim	Tablet (scored): 300 mg + 25 mg + 800 mg + 160 mg
<b>6.4.3 Other antivirals</b>	
ribavirin*	<p>Injection for intravenous administration: 800 mg and 1 g in 10-mL phosphate buffer solution.</p> <p>Solid oral dosage form: 200 mg; 400 mg; 600 mg.</p> <p>* For the treatment of viral haemorrhagic fevers only.</p>
<b>Complementary List</b>	
oseltamivir*	<p>Capsule: 30 mg; 45 mg; 75 mg (as phosphate).</p> <p>Oral powder: 12 mg/ mL.</p> <p>* Severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients</p>
valganciclovir*	<p>Powder for oral solution: 50 mg/mL</p> <p>Tablet: 450 mg.</p> <p>*For the treatment of cytomegalovirus retinitis (CMVr).</p>
<b>6.4.4 Antihepatitis medicines</b>	
<b>6.4.4.1 Medicines for hepatitis B</b>	
<b>6.4.4.1.1 Nucleoside/Nucleotide reverse transcriptase inhibitors</b>	

entecavir	<b>Oral liquid:</b> 0.05 mg/ mL <b>Tablet:</b> 0.5 mg; 1 mg
<b>6.4.4.2 Medicines for hepatitis C</b>	
<b>6.5 Antiprotozoal medicines</b>	
<b>6.5.1 Antiamoebic and anti giardiasis medicines</b>	
diloxanide <input type="checkbox"/> <sup>a</sup>	<b>Tablet:</b> 500 mg (furoate). <input type="checkbox"/> <sup>a</sup> >25 kg.
<input type="checkbox"/> metronidazole	<b>Injection:</b> 500 mg in 100-mL vial. <b>Oral liquid:</b> 200 mg (as benzoate)/5 mL. <b>Tablet:</b> 200 mg to 500 mg.
<b>6.5.2 Antileishmaniasis medicines</b>	
amphotericin B	<b>Powder for injection:</b> 50 mg in vial. As sodium deoxycholate <b>or</b> liposomal complex.
miltefosine	<b>Solid oral dosage form:</b> 10 mg; 50 mg.
paromomycin	<b>Solution for intramuscular injection:</b> 750 mg of paromomycin base (as the sulfate).
sodium stibogluconate <b>or</b> meglumine antimoniate	<b>Injection:</b> 100 mg/mL, 1 vial = 30 mL <b>or</b> 30%, equivalent to approximately 8.1% antimony (pentavalent) in 5-mL ampoule.
<b>6.5.3 Antimalarial medicines</b>	
<b>6.5.3.1 For curative treatment</b>	
Medicines for the treatment of <i>P. falciparum</i> malaria cases should be used in combination. The list currently recommends combinations according to treatment guidelines. WHO recognizes that not all of the fixed dose combinations (FDCs in the WHO treatment guidelines exist, and encourages their development and rigorous testing. WHO also encourages development and testing of rectal dosage formulations.	
amodiaquine*	<b>Tablet:</b> 153 mg <b>or</b> 200 mg (as hydrochloride). * To be used in combination with artesunate 50 mg.
artemether*	<b>Oily injection:</b> 80 mg/mL in 1-mL ampoule. * For use in the management of severe malaria.
artemether + lumefantrine*	<b>Tablet:</b> 20 mg + 120 mg. <b>Tablet (dispersible):</b> 20 mg + 120 mg. * Not recommended in the first trimester of pregnancy or in children below 5 kg.
artesunate*	<b>Injection:</b> ampoules, containing 60 mg anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution. For use in the management of severe malaria. <b>Rectal dosage form:</b> 50 mg; 100 mg; 200 mg capsules (for pre-referral treatment of severe malaria only; patients should be taken to an appropriate health facility for follow-up care). <b>Tablet:</b> 50 mg. * To be used in combination with either amodiaquine, mefloquine <b>or</b> sulfadoxine + pyrimethamine.

artesunate + amodiaquine *	<b>Tablet:</b> 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg. * Other combinations that deliver the target doses required such as 153 mg <b>or</b> 200 mg (as hydrochloride) with 50 mg artesunate can be alternatives.
artesunate + mefloquine	<b>Tablet:</b> 25 mg + 55 mg; 100 mg + 220 mg.
artesunate + pyronaridine tetraphosphate <b>a</b>	<b>Tablet:</b> 60 mg + 180 mg <b>Granules:</b> 20 mg + 60 mg <b>a</b> > 5 kg
chloroquine*	<b>Oral liquid:</b> 50 mg (as phosphate <b>or</b> sulfate)/5 mL. <b>Tablet:</b> 100 mg; 150 mg (as phosphate <b>or</b> sulfate). * For use only for the treatment of <i>P.vivax</i> infection.
dihydroartemisinin + piperaquine phosphate <b>a</b>	<b>Tablet:</b> 20 mg + 160 mg; 40 mg + 320 mg <b>a</b> > 5 kg
doxycycline*	<b>Capsule:</b> 100 mg (as hydrochloride <b>or</b> hyclate). <b>Tablet (dispersible):</b> 100 mg (as monohydrate). * For use only in combination with quinine.
mefloquine*	<b>Tablet:</b> 250 mg (as hydrochloride). * To be used in combination with artesunate 50 mg.
primaquine*	<b>Tablet:</b> 7.5 mg; 15 mg (as diphosphate). * Only for use to achieve radical cure of <i>P.vivax</i> and <i>P.ovale</i> infections, given for 14 days.
quinine*	<b>Injection:</b> 300 mg quinine hydrochloride/mL in 2-mL ampoule. <b>Tablet:</b> 300 mg (quinine sulfate) <b>or</b> 300 mg (quinine bisulfate). * For use only in the management of severe malaria, and should be used in combination with doxycycline.
sulfadoxine + pyrimethamine*	<b>Tablet:</b> 500 mg + 25 mg. * Only in combination with artesunate 50 mg.
<b>6.5.3.2 For prophylaxis</b>	
amodiaquine – sulfadoxine + pyrimethamine	<b>Co-packaged dispersible tablets:</b> amodiaquine 76.5 mg (as hydrochloride [3] and sulfadoxine + pyrimethamine 250 mg + 12.5 mg [1]; amodiaquine 153 mg (as hydrochloride) [3] and sulfadoxine + pyrimethamine 500 mg + 25 mg [1];
chloroquine*	<b>Oral liquid:</b> 50 mg (as phosphate <b>or</b> sulfate)/5 mL. <b>Tablet:</b> 150 mg (as phosphate <b>or</b> sulfate). * For use only for the treatment of <i>P.vivax</i> infection.
doxycycline <b>a</b>	<b>Solid oral dosage form:</b> 100 mg (as hydrochloride <b>or</b> hyclate). <b>a</b> >8 years.
mefloquine <b>a</b>	<b>Tablet:</b> 250 mg (as hydrochloride). <b>a</b> >5 kg <b>or</b> >3 months.

proguanil*	<b>Tablet:</b> 100 mg (as hydrochloride). * For use only in combination with chloroquine.
sulfadoxine + pyrimethamine	<b>Tablet:</b> 250 mg + 12.5 mg.
<b>6.5.4 Antipneumocystosis and antitoxoplasmosis medicines</b>	
pyrimethamine	<b>Tablet:</b> 25 mg.
sulfadiazine	<b>Tablet:</b> 500 mg.
sulfamethoxazole + trimethoprim	<b>Injection:</b> 80 mg + 16 mg/mL in 5-mL ampoule; 80 mg + 16 mg/mL in 10-mL ampoule. <b>Oral liquid:</b> 200 mg + 40 mg/5 mL. <b>Tablet:</b> 100 mg + 20 mg; 400 mg + 80 mg.
<b>6.5.5 Antitrypanosomal medicines</b>	
<b>6.5.5.1 African trypanosomiasis</b>	
fexinidazole*	<b>Tablet:</b> 600 mg * For the treatment of 1 <sup>st</sup> and 2 <sup>nd</sup> stage of human African trypanosomiasis due to <i>Trypanosoma brucei gambiense</i> infection.
<b>Medicines for the treatment of 1<sup>st</sup> stage African trypanosomiasis.</b>	
pentamidine*	<b>Powder for injection:</b> 200 mg (as isetionate) in vial. * To be used for the treatment of <i>Trypanosoma brucei gambiense</i> infection.
suramin sodium*	<b>Powder for injection:</b> 1 g in vial. * To be used for the treatment of the initial phase of <i>Trypanosoma brucei rhodesiense</i> infection.
<b>Medicines for the treatment of 2<sup>nd</sup> stage African trypanosomiasis</b>	
eflornithine*	<b>Injection:</b> 200 mg (hydrochloride)/mL in 100-mL bottle. * To be used for the treatment of <i>Trypanosoma brucei gambiense</i> infection.
nifurtimox*	<b>Tablet:</b> 120 mg. * Only to be used in combination with eflornithine, for the treatment of <i>Trypanosoma brucei gambiense</i> infection.
<b>Complementary List</b>	
melarsoprol	<b>Injection:</b> 3.6% solution in 5-mL ampoule (180 mg of active compound).
<b>6.5.5.2 American trypanosomiasis</b>	
benznidazole	<b>Tablet:</b> 12.5 mg; 100 mg. <b>Tablet (scored):</b> 50 mg.
nifurtimox	<b>Tablet:</b> 30 mg; 120 mg; 250 mg.
<b>6.6 Medicines for ectoparasitic infections</b>	
ivermectin	<b>Tablet (scored):</b> 3 mg



<b>7. ANTIMIGRAINE MEDICINES</b>	
<b>7.1 For treatment of acute attack</b>	
ibuprofen	<b>Tablet:</b> 200 mg; 400 mg.
paracetamol	<b>Oral liquid:</b> 120 mg/5 mL; 125 mg/5 mL. <b>Tablet:</b> 300 mg to 500 mg.
<b>7.2 For prophylaxis</b>	
propranolol	<b>Tablet:</b> 20 mg; 40 mg (hydrochloride).
<b>8. IMMUNOMODULATORS AND ANTINEOPLASTICS</b>	
<b>8.1 Immunomodulators for non-malignant disease</b>	
<i>Complementary List</i>	
<input type="checkbox"/> <i>adalimumab</i> *	<b>Injection:</b> 40 mg/0.8 mL; 40 mg/0.4 mL * <i>etanercept and infliximab are alternatives, including quality-assured biosimilars.</i>
<i>azathioprine</i>	<b>Powder for injection:</b> 100 mg (as sodium salt) in vial. <b>Tablet (scored):</b> 50 mg.
<i>ciclosporin</i>	<b>Capsule:</b> 25 mg. <b>Concentrate for injection:</b> 50 mg/mL in 1-mL ampoule for organ transplantation.
<b>8.2 Antineoplastic and supportive medicines</b>	
Medicines listed below should be used according to protocols for treatment of the diseases.	
<b>8.2.1 Cytotoxic medicines</b>	
<i>Complementary List</i>	
<i>arsenic trioxide</i>	<b>Concentrate for solution for infusion:</b> 1 mg/mL – <i>Acute promyelocytic leukaemia</i>
<i>asparaginase</i>	<b>Powder for injection:</b> 10 000 IU in vial. – <i>Acute lymphoblastic leukaemia.</i>
<i>bleomycin</i>	<b>Powder for injection:</b> 15 mg (as sulfate) in vial. – <i>Hodgkin lymphoma</i> – <i>Testicular germ cell tumours</i> – <i>Ovarian germ cell tumours</i> – <i>Kaposi sarcoma</i>
<i>calcium folinate</i>	<b>Injection:</b> 3 mg/ mL in 10- mL ampoule. <b>Tablet:</b> 5 mg; 15 mg; 25 mg. – <i>Osteosarcoma</i> – <i>Burkitt lymphoma</i>
<i>carboplatin</i>	<b>Injection:</b> 50 mg/5 mL; 150 mg/15 mL; 450 mg/45 mL; 600 mg/60 mL. – <i>Osteosarcoma</i> – <i>Retinoblastoma</i>

<i>cisplatin</i>	<p><b>Injection:</b> 50 mg/50 mL; 100 mg/100 mL.</p> <ul style="list-style-type: none"> <li>– Osteosarcoma</li> <li>– Testicular germ cell tumours</li> <li>– Ovarian germ cell tumours</li> <li>– Nasopharyngeal cancer</li> </ul>
<i>cyclophosphamide</i>	<p><b>Powder for injection:</b> 500 mg in vial.</p> <p><b>Tablet:</b> 25 mg; 50 mg.</p> <ul style="list-style-type: none"> <li>– Rhabdomyosarcoma</li> <li>– Ewing sarcoma</li> <li>– Acute lymphoblastic leukaemia</li> <li>– Burkitt lymphoma</li> <li>– Hodgkin lymphoma</li> <li>– Diffuse large B-cell lymphoma</li> </ul>
<i>cytarabine</i>	<p><b>Powder for injection:</b> 100 mg in vial.</p> <ul style="list-style-type: none"> <li>– Acute lymphoblastic leukaemia</li> <li>– Burkitt lymphoma.</li> <li>– Acute myeloid leukaemia</li> <li>– Acute promyelocytic leukaemia.</li> </ul>
<i>dacarbazine</i>	<p><b>Powder for injection:</b> 100 mg in vial.</p> <ul style="list-style-type: none"> <li>– Hodgkin lymphoma</li> </ul>
<i>dactinomycin</i>	<p><b>Powder for injection:</b> 500 micrograms in vial.</p> <ul style="list-style-type: none"> <li>– Rhabdomyosarcoma</li> <li>– Nephroblastoma (Wilms tumour)</li> </ul>
<i>daunorubicin</i>	<p><b>Powder for injection:</b> 50 mg (hydrochloride) in vial.</p> <ul style="list-style-type: none"> <li>– Acute lymphoblastic leukaemia</li> <li>– Acute promyelocytic leukaemia.</li> </ul>
<i>doxorubicin</i>	<p><b>Powder for injection:</b> 10 mg; 50 mg (hydrochloride) in vial.</p> <ul style="list-style-type: none"> <li>– Osteosarcoma</li> <li>– Ewing sarcoma</li> <li>– Acute lymphoblastic leukaemia</li> <li>– Nephroblastoma (Wilms tumour)</li> <li>– Burkitt lymphoma</li> <li>– Hodgkin lymphoma</li> <li>– Diffuse large B-cell lymphoma</li> <li>– Kaposi sarcoma</li> </ul>
<i>etoposide</i>	<p><b>Capsule:</b> 50 mg; 100 mg.</p> <p><b>Injection:</b> 20 mg/ mL in 5- mL ampoule.</p> <ul style="list-style-type: none"> <li>– Retinoblastoma</li> <li>– Ewing sarcoma</li> <li>– Acute lymphoblastic leukaemia</li> <li>– Burkitt lymphoma</li> <li>– Hodgkin lymphoma</li> <li>– Testicular germ cell tumours</li> <li>– Ovarian germ cell tumours</li> </ul>

<i>fluorouracil</i>	<b>Injection:</b> 50 mg/ mL in 5- mL ampoule. – Nasopharyngeal cancer – Metastatic colorectal cancer – Early stage colon cancer – Early stage rectal cancer
<i>hydroxycarbamide</i>	<b>Solid oral dosage form:</b> 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g. – Chronic myeloid leukaemia.
<i>ifosfamide</i>	<b>Powder for injection:</b> 500 mg vial 1-g vial; 2-g vial. – Osteosarcoma – Rhabdomyosarcoma – Ewing sarcoma – Testicular germ cell tumours – Ovarian germ cell tumours
<i>irinotecan</i>	<b>Injection:</b> 40 mg/2 mL in 2- mL vial; 100 mg/5 mL in 5- mL vial; 500 mg/25 mL in 25- mL vial. – Metastatic colorectal cancer.
<i>mercaptopurine</i>	<b>Tablet:</b> 50 mg. – Acute lymphoblastic leukaemia – Acute promyelocytic leukaemia.
<i>methotrexate</i>	<b>Powder for injection:</b> 50 mg (as sodium salt) in vial. <b>Tablet:</b> 2.5 mg (as sodium salt). – Osteosarcoma – Acute lymphoblastic leukaemia – Acute promyelocytic leukaemia.
<i>oxaliplatin</i>	<b>Injection:</b> 50 mg/10 mL in 10- mL vial; 100 mg/20 mL in 20- mL vial; 200 mg/40 mL in 40- mL vial. <b>Powder for injection:</b> 50 mg, 100 mg in vial. – Early stage colon cancer – Metastatic colorectal cancer
<i>paclitaxel</i>	<b>Powder for injection:</b> 6 mg/ mL. – Ovarian germ cell tumours
<i>pegaspargase*</i>	<b>Injection:</b> 3,750 units/5 mL in vial – Acute lymphoblastic leukaemia. * including quality-assured biosimilars
<i>procarbazine</i>	<b>Capsule:</b> 50 mg (as hydrochloride). – Hodgkin lymphoma
<i>realgar-Indigo naturalis formulation</i>	<b>Tablet:</b> 270 mg (containing tetra-arsenic tetra-sulfide 30 mg) – Acute promyelocytic leukaemia
<i>tioguanine</i>	<b>Solid oral dosage form:</b> 40 mg. – Acute lymphoblastic leukaemia.

vinblastine	<p><b>Powder for injection:</b> 10 mg (sulfate) in vial.</p> <ul style="list-style-type: none"> <li>– Testicular germ cell tumours</li> <li>– Ovarian germ cell tumours</li> <li>– Hodgkin lymphoma</li> </ul>
vincristine	<p><b>Powder for injection:</b> 1 mg; 5 mg (sulfate) in vial.</p> <ul style="list-style-type: none"> <li>– Retinoblastoma</li> <li>– Rhabdomyosarcoma</li> <li>– Ewing sarcoma</li> <li>– Acute lymphoblastic leukaemia</li> <li>– Nephroblastoma (Wilms tumour)</li> <li>– Burkitt lymphoma.</li> <li>– Hodgkin lymphoma</li> <li>– Diffuse large B-cell lymphoma</li> <li>– Kaposi sarcoma</li> </ul>
<b>8.2.2 Targeted therapies</b>	
<b>Complementary List</b>	
all-trans retinoid acid (ATRA)	<p><b>Capsule:</b> 10 mg.</p> <ul style="list-style-type: none"> <li>– Acute promyelocytic leukaemia.</li> </ul>
dasatinib	<p><b>Tablet:</b> 20 mg; 50 mg; 70 mg; 80 mg; 100 mg; 140 mg.</p> <ul style="list-style-type: none"> <li>– Imatinib-resistant chronic myeloid leukaemia</li> </ul>
imatinib	<p><b>Tablet:</b> 100 mg; 400 mg.</p> <ul style="list-style-type: none"> <li>– Chronic myeloid leukaemia</li> <li>– Gastrointestinal stromal tumour</li> </ul>
nilotinib	<p><b>Capsule:</b> 150 mg; 200 mg.</p> <ul style="list-style-type: none"> <li>– Imatinib-resistant chronic myeloid leukaemia</li> </ul>
rituximab*	<p><b>Injection (intravenous):</b> 100 mg/10 mL in 10- mL vial; 500 mg/50 mL in 50- mL vial.</p> <ul style="list-style-type: none"> <li>– Diffuse large B-cell lymphoma</li> </ul> <p>* including quality-assured biosimilars</p>
<b>8.2.3 Immunomodulators</b>	
<b>Complementary List</b>	
filgrastim	<p><b>Injection:</b> 120 micrograms/0.2 mL; 300 micrograms/0.5 mL; 480 micrograms/0.8 mL in pre-filled syringe 300 micrograms/mL in 1- mL vial, 480 micrograms/1.6 mL in 1.6- mL vial.</p> <ul style="list-style-type: none"> <li>– Primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy.</li> <li>– Secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy</li> <li>– To facilitate administration of dose dense chemotherapy regimens</li> </ul>
<b>8.2.4 Hormones and antihormones</b>	
<b>Complementary List</b>	

dexamethasone	<p><b>Injection:</b> 4 mg/ mL in 1- mL ampoule (as disodium phosphate salt).</p> <p><b>Oral liquid:</b> 2 mg/5 mL</p> <p><b>Tablet:</b> 2 mg; 4 mg.</p> <p>– Acute lymphoblastic leukaemia</p>
hydrocortisone	<p><b>Powder for injection:</b> 100 mg (as sodium succinate) in vial.</p> <p>– Acute lymphoblastic leukaemia.</p>
methylprednisolone	<p><b>Injection:</b> 40 mg/ mL (as sodium succinate) in 1- mL single-dose vial and 5- mL multi-dose vials; 80 mg/ mL (as sodium succinate) in 1- mL single-dose vial.</p> <p>– Acute lymphoblastic leukaemia.</p>
□ prednisolone	<p><b>Oral liquid:</b> 5 mg/ mL</p> <p><b>Tablet:</b> 5 mg; 25 mg.</p> <p>– Acute lymphoblastic leukaemia – Burkitt lymphoma – Hodgkin lymphoma – Diffuse large B-cell lymphoma</p>
<b>8.2.5 Supportive medicines</b>	
<b>Complementary List</b>	
allopurinol	<p><b>Tablet:</b> 100 mg; 300 mg.</p> <p>– Tumour lysis syndrome</p>
mesna	<p><b>Injection:</b> 100 mg/ mL in 4- mL and 10- mL ampoules.</p> <p><b>Tablet:</b> 400 mg; 600 mg.</p> <p>– Osteosarcoma – Rhabdomyosarcoma – Ewing sarcoma. – Testicular germ cell tumours – Ovarian germ cell tumours</p>
<b>9. ANTIPARKINSONISM MEDICINES</b>	
<b>10. MEDICINES AFFECTING THE BLOOD</b>	
<b>10.1 Antianaemia medicines</b>	
ferrous salt	<p><b>Oral liquid:</b> equivalent to 25 mg iron (as sulfate)/mL.</p> <p><b>Tablet:</b> equivalent to 60 mg iron.</p>
folic acid	<b>Tablet:</b> 1 mg; 5 mg.
hydroxocobalamin	<b>Injection:</b> 1 mg (as acetate, as hydrochloride or as sulfate) in 1-mL ampoule.
<b>Complementary List</b>	

<input type="checkbox"/> erythropoiesis-stimulating agents*	<p><b>Injection: pre-filled syringe</b></p> <p>1000IU/ 0.5 mL; 2000IU/ 0.5 mL; 3000IU/ 0.3 mL; 4000IU/ 0.4 mL; 5000IU/ 0.5 mL; 6000IU/ 0.6 mL; 8000IU/ 0.8mL; 10 000IU/ 1 mL; 20 000IU/ 0.5 mL; 40 000IU/ 1 mL</p> <p>* the square box applies to epoetin alfa, beta and theta, darbepoetin alfa, and their respective biosimilars</p>
<b>10.2 Medicines affecting coagulation</b>	
<input type="checkbox"/> enoxaparin*	<p><b>Injection: ampoule or pre-filled syringe</b></p> <p>20 mg/0.2 mL; 40 mg/0.4 mL; 60 mg/0.6 mL; 80 mg/0.8 mL; 100 mg/1 mL; 120 mg/0.8 mL; 150 mg/1 mL</p> <p>*Alternatives are limited to nadroparin and dalteparin</p>
phytomenadione	<p><b>Injection:</b> 1 mg/mL; 10 mg/mL in ampoule.</p> <p><b>Tablet:</b> 10 mg.</p>
<b>Complementary List</b>	
<i>desmopressin</i>	<p><b>Injection:</b> 4 micrograms/ mL (as acetate) in 1- mL ampoule.</p> <p><b>Nasal spray:</b> 10 micrograms (as acetate) per dose</p>
<i>heparin sodium</i>	<p><b>Injection:</b> 1000 IU/mL; 5000 IU/mL in 1-mL ampoule.</p>
<i>protamine sulfate</i>	<p><b>Injection:</b> 10 mg/mL in 5-mL ampoule.</p>
<input type="checkbox"/> warfarin	<p><b>Tablet:</b> 0.5 mg; 1 mg; 2 mg; 5 mg (sodium salt).</p>

<b>10.3 Other medicines for haemoglobinopathies</b>	
<i>Complementary list</i>	
<i>deferoxamine*</i>	<b>Powder for injection:</b> 500 mg (mesilate) in vial. * <i>Deferasirox oral form may be an alternative, depending on cost and availability.</i>
<i>hydroxycarbamide</i>	<b>Solid oral dosage form:</b> 200 mg; 500 mg; 1 g.
<b>11. BLOOD PRODUCTS OF HUMAN ORIGIN AND PLASMA SUBSTITUTES</b>	
<b>11.1 Blood and blood components</b>	
In accordance with the World Health Assembly resolution WHA63.12, WHO recognizes that achieving self-sufficiency, unless special circumstances preclude it, in the supply of safe blood components based on voluntary, non-remunerated blood donation, and the security of that supply are important national goals to prevent blood shortages and meet the transfusion requirements of the patient population. All preparations should comply with the WHO requirements.	
fresh-frozen plasma	
platelets	
red blood cells	
whole blood	
<b>11.2 Plasma-derived medicines</b>	
All human plasma-derived medicines should comply with the WHO requirements.	
<b>11.2.1 Human immunoglobulins</b>	
anti-rabies immunoglobulin	<b>Injection:</b> 150 IU/ mL in vial.
anti-tetanus immunoglobulin	<b>Injection:</b> 500 IU in vial.
<i>Complementary List</i>	
<i>normal immunoglobulin</i>	<b>Intramuscular administration:</b> 16% protein solution.* <b>Intravenous administration:</b> 5%; 10% protein solution.** <b>Subcutaneous administration:</b> 15%; 16% protein solution.* * <i>Indicated for primary immune deficiency.</i> ** <i>Indicated for primary immune deficiency and Kawasaki disease.</i>
<b>11.2.2 Blood coagulation factors</b>	
<i>Complementary List</i>	
<input type="checkbox"/> <i>coagulation factor VIII</i>	<b>Powder for injection:</b> 500 IU/vial.
<input type="checkbox"/> <i>coagulation factor IX</i>	<b>Powder for injection:</b> 500 IU/vial, 1000 IU/vial.

<b>11.3 Plasma substitutes</b>	
<input type="checkbox"/> dextran 70*	<b>Injectable solution:</b> 6%. * Polygeline, injectable solution, 3.5% is considered as equivalent.
<b>12. CARDIOVASCULAR MEDICINES</b>	
<b>12.1 Antianginal medicines</b>	
<b>12.2 Antiarrhythmic medicines</b>	
<b>12.3 Antihypertensive medicines</b>	
<input type="checkbox"/> enalapril	<b>Tablet:</b> 2.5 mg; 5 mg (as hydrogen maleate).
<b>12.4 Medicines used in heart failure</b>	
digoxin	<b>Injection:</b> 250 micrograms/mL in 2-mL ampoule. <b>Oral liquid:</b> 50 micrograms/mL. <b>Tablet:</b> 62.5 micrograms; 250 micrograms.
furosemide	<b>Injection:</b> 10 mg/mL in 2-mL ampoule. <b>Oral liquid:</b> 20 mg/5 mL. <b>Tablet:</b> 40 mg.
<i>Complementary List</i>	
dopamine	<b>Injection:</b> 40 mg (hydrochloride) in 5-mL vial.
<b>12.5 Antithrombotic medicines</b>	
<b>12.6 Lipid-lowering agents</b>	
<b>13. DERMATOLOGICAL MEDICINES (topical)</b>	
<b>13.1 Antifungal medicines</b>	
<input type="checkbox"/> miconazole	<b>Cream or ointment:</b> 2% (nitrate).
terbinafine	<b>Cream:</b> 1% or <b>Ointment:</b> 1% terbinafine hydrochloride.
<b>13.2 Anti-infective medicines</b>	
mupirocin	<b>Cream (as mupirocin calcium):</b> 2%. <b>Ointment:</b> 2%.
potassium permanganate	<b>Aqueous solution:</b> 1:10 000.
silver sulfadiazine <sup>a</sup>	<b>Cream:</b> 1%. <sup>a</sup> >2 months.
<b>13.3 Anti-inflammatory and antipruritic medicines</b>	
<input type="checkbox"/> betamethasone <sup>a</sup>	<b>Cream or ointment:</b> 0.1% (as valerate). <sup>a</sup> Hydrocortisone preferred in neonates.
calamine	<b>Lotion.</b>
hydrocortisone	<b>Cream or ointment:</b> 1% (acetate).
<b>13.4 Medicines affecting skin differentiation and proliferation</b>	
benzoyl peroxide	<b>Cream or lotion:</b> 5%.



coal tar	<b>Solution:</b> 5%.
<input type="checkbox"/> podophyllum resin	<b>Solution:</b> 10% to 25%.
salicylic acid	<b>Solution:</b> 5%.
urea	<b>Cream or ointment:</b> 5%; 10%.
<b>13.5 Scabicides and pediculicides</b>	
<input type="checkbox"/> benzyl benzoate <sup>a</sup>	<b>Lotion:</b> 25%. <sup>a</sup> >2 years.
permethrin	<b>Cream:</b> 5%. <b>Lotion:</b> 1%.
<b>14. DIAGNOSTIC AGENTS</b>	
<b>14.1 Ophthalmic medicines</b>	
fluorescein	<b>Eye drops:</b> 1% (sodium salt).
<input type="checkbox"/> tropicamide	<b>Eye drops:</b> 0.5%.
<b>14.2 Radiocontrast media</b>	
<i>Complementary List</i>	
<i>barium sulfate</i>	<i>Aqueous suspension.</i>
<b>15. DISINFECTANTS AND ANTISEPTICS</b>	
<b>15.1 Antiseptics</b>	
<input type="checkbox"/> chlorhexidine	<b>Solution:</b> 5% (digluconate). <b>Gel:</b> 4%.
<input type="checkbox"/> ethanol	<b>Solution:</b> 70% (denatured).
<input type="checkbox"/> povidone iodine	<b>Solution:</b> 10% (equivalent to 1% available iodine).
<b>15.2 Disinfectants</b>	
alcohol based hand rub	<b>Solution</b> containing ethanol 80% volume /volume <b>Solution</b> containing isopropyl alcohol 75% volume/volume
<input type="checkbox"/> chlorine base compound	<b>Powder:</b> (0.1% available chlorine) for solution.
<input type="checkbox"/> chloroxylenol	<b>Solution:</b> 4.8%.
glutaral	<b>Solution:</b> 2%.

<b>16. DIURETICS</b>	
furosemide	<b>Injection:</b> 10 mg/mL in 2-mL ampoule. <b>Oral liquid:</b> 20 mg/5 mL. <b>Tablet:</b> 10 mg; 20 mg; 40 mg.
<i>Complementary List</i>	
<input type="checkbox"/> hydrochlorothiazide	<b>Tablet (scored):</b> 25 mg.
mannitol	<b>Injectable solution:</b> 10%; 20%.
spironolactone	<b>Oral liquid:</b> 5 mg/5 mL; 10 mg/5 mL; 25 mg/5 mL. <b>Tablet:</b> 25 mg.
<b>17. GASTROINTESTINAL MEDICINES</b>	
<i>Complementary List</i>	
<input type="checkbox"/> pancreatic enzymes	Age-appropriate formulations and doses including lipase, protease and amylase.
<b>17.1 Antiulcer medicines</b>	
<input type="checkbox"/> omeprazole	<b>Powder for oral liquid:</b> 20-mg; 40-mg sachets. <b>Solid oral dosage form:</b> 10 mg; 20 mg; 40 mg.
<input type="checkbox"/> ranitidine	<b>Injection:</b> 25 mg/mL (as hydrochloride) in 2-mL ampoule. <b>Oral liquid:</b> 75 mg/5 mL (as hydrochloride). <b>Tablet:</b> 150 mg (as hydrochloride).
<b>17.2 Antiemetic medicines</b>	
dexamethasone	<b>Injection:</b> 4 mg/mL in 1-mL ampoule (as disodium phosphate salt). <b>Oral liquid:</b> 0.5 mg/5 mL; 2 mg/5 mL. <b>Solid oral dosage form:</b> 0.5 mg; 0.75 mg; 1.5 mg; 4 mg.
metoclopramide <sup>a</sup>	<b>Injection:</b> 5 mg (hydrochloride)/mL in 2-mL ampoule. <b>Oral liquid:</b> 5 mg/5 mL. <b>Tablet:</b> 10 mg (hydrochloride). <sup>a</sup> Not in neonates.
<input type="checkbox"/> ondansetron <sup>a</sup>	<b>Injection:</b> 2 mg base/mL in 2-mL ampoule (as hydrochloride). <b>Oral liquid:</b> 4 mg base/5 mL. <b>Solid oral dosage form:</b> Eq 4 mg base; Eq 8 mg base. <sup>a</sup> >1 month.
<i>Complementary list</i>	
aprepitant	<b>Capsule:</b> 80 mg; 125 mg; 165 mg <b>Powder for oral suspension:</b> 125 mg in sachet
<b>17.3 Anti-inflammatory medicines</b>	
<b>17.4 Laxatives</b>	
<b>17.5 Medicines used in diarrhoea</b>	

oral rehydration salts – zinc sulfate	<b>Co-package containing:</b> <b>ORS powder for dilution</b> (see Section 17.5.1) – zinc sulfate <b>solid oral dosage form</b> 20 mg (see Section 17.5.2)
<b>17.5.1 Oral rehydration</b>	
oral rehydration salts	<b>Powder for dilution</b> in 200 mL; 500 mL; 1 L. glucose: 75 mEq sodium: 75 mEq <b>or</b> mmol/L chloride: 65 mEq <b>or</b> mmol/L potassium: 20 mEq <b>or</b> mmol/L citrate: 10 mmol/L osmolarity: 245 mOsm/L glucose: 13.5 g/L sodium chloride: 2.6 g/L potassium chloride: 1.5 g/L trisodium citrate dihydrate*: 2.9 g/L  * trisodium citrate dihydrate may be replaced by sodium hydrogen carbonate (sodium bicarbonate) 2.5 g/L. However, as the stability of this latter formulation is very poor under tropical conditions, it is recommended only when manufactured for immediate use.
<b>17.5.2 Medicines for diarrhoea</b>	
zinc sulfate*	<b>Solid oral dosage form:</b> 20 mg.  * In acute diarrhoea, zinc sulfate should be used as an adjunct to oral rehydration salts.
<b>18. MEDICINES FOR ENDOCRINE DISORDERS</b>	
<b>18.1 Adrenal hormones and synthetic substitutes</b>	
fludrocortisone	<b>Tablet:</b> 100 micrograms (acetate).
hydrocortisone	<b>Tablet:</b> 5 mg; 10 mg; 20 mg.
<b>18.2 Androgens</b>	
<b>18.3 Estrogens</b>	
<b>18.4 Progestogens</b>	
<b>18.5 Medicines for diabetes</b>	
<b>18.5.1 Insulins</b>	
insulin injection (soluble)	<b>Injection:</b> 100 IU/mL in 10-mL vial.
intermediate-acting insulin	<b>Injection:</b> 100 IU/mL in 10-mL vial (as compound insulin zinc suspension <b>or</b> isophane insulin).
<b>18.5.2 Oral hypoglycaemic agents</b>	
<b>Complementary List</b>	
<i>metformin</i>	<b>Tablet:</b> 500 mg (hydrochloride).
<b>18.6 Medicines for hypoglycaemia</b>	
glucagon	<b>Injection:</b> 1 mg/mL.
<b>Complementary List</b>	

<i>diazoxide</i>	<i>Oral liquid: 50 mg/mL</i> <i>Tablet: 50 mg</i>
<b>18.7 Thyroid hormones and antithyroid medicines</b>	
levothyroxine	<b>Tablet:</b> 25 micrograms; 50 micrograms; 100 micrograms (sodium salt).
<b>Complementary List</b>	
<i>Lugol's solution</i>	<b>Oral liquid:</b> about 130 mg total iodine/mL.
□ <i>methimazole*</i>	<b>Tablet:</b> 5mg, 10mg, 20mg. <i>* carbimazole is an alternative depending on local availability.</i>
<i>potassium iodide</i>	<b>Tablet:</b> 60 mg.
<i>propylthiouracil*</i>	<b>Tablet:</b> 50 mg. <i>*for use in patients for whom alternative first-line treatment is not appropriate or available</i>
<b>19. IMMUNOLOGICALS</b>	
<b>19.1 Diagnostic agents</b>	
All tuberculins should comply with the WHO requirements for tuberculins.	
tuberculin, purified protein derivative (PPD)	<b>Injection.</b>
<b>19.2 Sera and immunoglobulins</b>	
All plasma fractions should comply with the WHO requirements.	
anti-venom immunoglobulin*	<b>Injection.</b> <i>* Exact type to be defined locally.</i>
diphtheria antitoxin	<b>Injection:</b> 10 000 IU; 20 000 IU in vial.

<b>19.3 Vaccines</b>	
<p>WHO immunization policy recommendations are published in vaccine position papers on the basis of recommendations made by the Strategic Advisory Group of Experts on Immunization (SAGE).</p> <p>WHO vaccine position papers are updated three to four times per year. The list below details the vaccines for which there is a recommendation from SAGE and a corresponding WHO position paper as at <b>December 2018</b>. The most recent versions of the WHO position papers, reflecting the current evidence related to a specific vaccine and the related recommendations, can be accessed at any time on the WHO website at:</p> <p><a href="http://www.who.int/immunization/documents/positionpapers/en/index.html">http://www.who.int/immunization/documents/positionpapers/en/index.html</a>.</p> <p>Vaccine recommendations may be universal or conditional (e.g., in certain regions, in some high-risk populations or as part of immunization programmes with certain characteristics). Details are available in the relevant position papers, and in the Summary Tables of WHO Routine Immunization Recommendations available on the WHO website at:</p> <p><a href="http://www.who.int/immunization/policy/immunization_tables/en/index.html">http://www.who.int/immunization/policy/immunization_tables/en/index.html</a>.</p> <p>Selection of vaccines from the Model List will need to be determined by each country after consideration of international recommendations, epidemiology and national priorities.</p> <p>All vaccines should comply with the WHO requirements for biological substances.</p> <p>WHO noted the need for vaccines used in children to be polyvalent.</p>	
<b><i>Recommendations for all</i></b>	
BCG vaccine	
diphtheria vaccine	
Haemophilus influenzae type b vaccine	
hepatitis B vaccine	
HPV vaccine	
measles vaccine	
pertussis vaccine	
pneumococcal vaccine	
poliomyelitis vaccine	
rotavirus vaccine	
rubella vaccine	
tetanus vaccine	
<b><i>Recommendations for certain regions</i></b>	
Japanese encephalitis vaccine	
yellow fever vaccine	
tick-borne encephalitis vaccine	
<b><i>Recommendations for some high-risk populations</i></b>	
cholera vaccine	
dengue vaccine	
hepatitis A vaccine	

meningococcal meningitis vaccine	
rabies vaccine	
typhoid vaccine	
<i>Recommendations for immunization programmes with certain characteristics</i>	
influenza vaccine (seasonal)	
mumps vaccine	
varicella vaccine	
<b>20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE INHIBITORS</b>	
neostigmine	<b>Injection:</b> 500 micrograms in 1-mL ampoule; 2.5 mg (metilsulfate) in 1-mL ampoule. <b>Tablet:</b> 15 mg (bromide).
suxamethonium	<b>Injection:</b> 50 mg (chloride)/mL in 2-mL ampoule. <b>Powder for injection:</b> (chloride), in vial.
<input type="checkbox"/> vecuronium	<b>Powder for injection:</b> 10 mg (bromide) in vial.
<i>Complementary List</i>	
<i>pyridostigmine</i>	<b>Injection:</b> 1 mg in 1-mL ampoule. <b>Tablet:</b> 60 mg (bromide).
<b>21. OPHTHALMOLOGICAL PREPARATIONS</b>	
<b>21.1 Anti-infective agents</b>	
aciclovir	<b>Ointment:</b> 3% W/W.
azithromycin	<b>Solution (eye drops):</b> 1.5%
erythromycin*	<b>Ointment:</b> 0.5% <i>*Infections due to Chlamydia trachomatis or Neisseria gonorrhoeae.</i>
<input type="checkbox"/> gentamicin	<b>Solution (eye drops):</b> 0.3% (sulfate).
natamycin	<b>Suspension: (eye drops):</b> 5%
<input type="checkbox"/> ofloxacin	<b>Solution (eye drops):</b> 0.3%.
<input type="checkbox"/> tetracycline	<b>Eye ointment:</b> 1% (hydrochloride).
<b>21.2 Anti-inflammatory agents</b>	
<input type="checkbox"/> prednisolone	<b>Solution (eye drops):</b> 0.5% (sodium phosphate).
<b>21.3 Local anaesthetics</b>	
<input type="checkbox"/> tetracaine <sup>a</sup>	<b>Solution (eye drops):</b> 0.5% (hydrochloride). <sup>a</sup> Not in preterm neonates.
<b>21.4 Miotics and antiglaucoma medicines</b>	
<b>21.5 Mydriatics</b>	

atropine* <sup>a</sup>	<b>Solution (eye drops):</b> 0.1%; 0.5%; 1% (sulfate). * Or homatropine (hydrobromide) or cyclopentolate (hydrochloride). <sup>a</sup> >3 months.
<b>Complementary List</b>	
epinephrine (adrenaline)	<b>Solution (eye drops):</b> 2% (as hydrochloride).
<b>21.6 Anti-vascular endothelial growth factor (VEGF) preparations</b>	
<b>22. MEDICINES FOR REPRODUCTIVE HEALTH AND PERINATAL CARE</b>	
<b>22.1 Contraceptives</b>	
<b>22.2 Ovulation inducers</b>	
<b>22.3 Uterotonics</b>	
<b>22.4 Antioxytocics (tocolytics)</b>	
<b>22.5 Other medicines administered to the mother</b>	
<b>22.6 Medicines administered to the neonate</b>	
caffeine citrate	<b>Injection:</b> 20 mg/mL (equivalent to 10 mg caffeine base/mL). <b>Oral liquid:</b> 20 mg/mL (equivalent to 10 mg caffeine base/mL).
chlorhexidine	<b>Solution or gel:</b> 7.1% (digluconate) delivering 4% chlorhexidine (for umbilical cord care).
<b>Complementary List</b>	
<input type="checkbox"/> ibuprofen	<b>Solution for injection:</b> 5 mg/mL.
<input type="checkbox"/> prostaglandin E	<b>Solution for injection:</b> <b>Prostaglandin E1:</b> 0.5 mg/mL in alcohol. <b>Prostaglandin E2:</b> 1 mg/mL.
surfactant	<b>Suspension for intratracheal instillation:</b> 25 mg/mL or 80 mg/mL.
<b>23. PERITONEAL DIALYSIS SOLUTION</b>	
<b>Complementary List</b>	
intraperitoneal dialysis solution (of appropriate composition)	<b>Parenteral solution.</b>
<b>24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS</b>	
<b>24.1 Medicines used in psychotic disorders</b>	
<b>Complementary List</b>	
chlorpromazine	<b>Injection:</b> 25 mg (hydrochloride)/mL in 2-mL ampoule. <b>Oral liquid:</b> 25 mg (hydrochloride)/5 mL. <b>Tablet:</b> 10 mg; 25 mg; 50 mg; 100 mg (hydrochloride).
haloperidol	<b>Injection:</b> 5 mg in 1-mL ampoule. <b>Oral liquid:</b> 2 mg/mL. <b>Solid oral dosage form:</b> 0.5 mg; 2 mg; 5 mg.
<b>24.2 Medicines used in mood disorders</b>	

<b>24.2.1 Medicines used in depressive disorders</b>	
<i>Complementary List</i>	
fluoxetine <input type="checkbox"/>	<b>Solid oral dosage form:</b> 20 mg (as hydrochloride). <input type="checkbox"/> >8 years.
<b>24.2.2 Medicines used in bipolar disorders</b>	
<b>24.3 Medicines for anxiety disorders</b>	
<b>24.4 Medicines used for obsessive compulsive disorders</b>	
<b>24.5 Medicines for disorders due to psychoactive substance use</b>	
<b>25. MEDICINES ACTING ON THE RESPIRATORY TRACT</b>	
<b>25.1 Antiasthmatic medicines</b>	
<input type="checkbox"/> budesonide	<b>Inhalation (aerosol):</b> 100 micrograms per dose; 200 micrograms per dose.
epinephrine (adrenaline)	<b>Injection:</b> 1 mg (as hydrochloride <b>or</b> hydrogen tartrate) in 1-mL ampoule.
<input type="checkbox"/> salbutamol	<b>Injection:</b> 50 micrograms (as sulfate)/mL in 5-mL ampoule. <b>Metered dose inhaler (aerosol):</b> 100 micrograms (as sulfate) per dose. <b>Respirator solution for use in nebulizers:</b> 5 mg (as sulfate)/mL.
<b>26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES</b>	
<b>26.1 Oral</b>	
oral rehydration salts	See section 17.5.1.
potassium chloride	<b>Powder for solution.</b>
<b>26.2 Parenteral</b>	
glucose	<b>Injectable solution:</b> 5% (isotonic); 10% (hypertonic); 50% (hypertonic).
glucose with sodium chloride	<b>Injectable solution:</b> 5% glucose, 0.9% sodium chloride (equivalent to Na <sup>+</sup> 150 mmol/L and Cl <sup>-</sup> 150 mmol/L); 5% glucose, 0.45% sodium chloride (equivalent to Na <sup>+</sup> 75 mmol/L and Cl <sup>-</sup> 75 mmol/L).
potassium chloride	<b>Solution for dilution:</b> 7.5% (equivalent to K <sup>+</sup> 1 mmol/mL and Cl <sup>-</sup> 1 mmol/mL); 15% (equivalent to K <sup>+</sup> 2 mmol/mL and Cl <sup>-</sup> 2 mmol/mL).
sodium chloride	<b>Injectable solution:</b> 0.9% isotonic (equivalent to Na <sup>+</sup> 154 mmol/L, Cl <sup>-</sup> 154 mmol/L).
sodium hydrogen carbonate	<b>Injectable solution:</b> 1.4% isotonic (equivalent to Na <sup>+</sup> 167 mmol/L, HCO <sub>3</sub> <sup>-</sup> 167 mmol/L). <b>Solution:</b> 8.4% in 10-mL ampoule (equivalent to Na <sup>+</sup> 1000 mmol/L, HCO <sub>3</sub> <sup>-</sup> 1000 mmol/L).
<input type="checkbox"/> sodium lactate, compound solution	<b>Injectable solution.</b>
<b>26.3 Miscellaneous</b>	
water for injection	2-mL; 5-mL; 10-mL ampoules.



27. VITAMINS AND MINERALS	
ascorbic acid	<b>Tablet:</b> 50 mg.
colecalfiferol*	<b>Oral liquid:</b> 400 IU/mL. <b>Solid oral dosage form:</b> 400 IU; 1000 IU. * Ergocalciferol can be used as an alternative.
iodine	<b>Capsule:</b> 190 mg. <b>Iodized oil:</b> 1 mL (480 mg iodine); 0.5 mL (240 mg iodine) in ampoule (oral <b>or</b> injectable); 0.57 mL (308 mg iodine) in dispenser bottle.
multiple micronutrient powder	<b>Sachets containing:</b> - iron (elemental) 12.5 mg (as coated ferrous fumarate) - zinc (elemental) 5 mg - vitamin A 300 micrograms - with or without other micronutrients at recommended daily values
pyridoxine	<b>Tablet:</b> 25 mg (hydrochloride).
retinol	<b>Capsule:</b> 100 000 IU; 200 000 IU (as palmitate). <b>Oral oily solution:</b> 100 000 IU (as palmitate)/mL in multidose dispenser. <b>Tablet (sugar-coated):</b> 10 000 IU (as palmitate). <b>Water-miscible injection:</b> 100 000 IU (as palmitate) in 2-mL ampoule.
riboflavin	<b>Tablet:</b> 5 mg.
sodium fluoride	In any appropriate topical formulation.
thiamine	<b>Tablet:</b> 50 mg (hydrochloride).
<b>Complementary List</b>	
<i>calcium gluconate</i>	<b>Injection:</b> 100 mg/mL in 10-mL ampoule.
28. EAR, NOSE AND THROAT MEDICINES	
acetic acid	<b>Topical:</b> 2%, in alcohol.
<input type="checkbox"/> budesonide	<b>Nasal spray:</b> 100 micrograms per dose.
<input type="checkbox"/> ciprofloxacin	<b>Topical:</b> 0.3% drops (as hydrochloride).
<input type="checkbox"/> xylometazoline <sup>a</sup>	<b>Nasal spray:</b> 0.05%. <sup>a</sup> Not in children less than 3 months.
29. MEDICINES FOR DISEASES OF JOINTS	
29.1 Medicines used to treat gout	
29.2 Disease-modifying agents used in rheumatoid disorders (DMARDs)	
<b>Complementary List</b>	
<i>hydroxychloroquine</i>	<b>Solid oral dosage form:</b> 200 mg (as sulfate).

<i>methotrexate</i>	<b>Tablet:</b> 2.5 mg (as sodium salt).
<b>29.3 Juvenile joint diseases</b>	
<i>acetylsalicylic acid* (acute or chronic use)</i>	<b>Suppository:</b> 50 mg to 150 mg. <b>Tablet:</b> 100 mg to 500 mg. <i>* For use for rheumatic fever, juvenile arthritis, Kawasaki disease.</i>

## Index

abacavir (ABC).....	16	<i>ceftazidime</i> .....	12
abacavir + lamivudine .....	17	<i>ceftazidime + avibactam</i> .....	12
acetic acid .....	39	ceftriaxone .....	11
acetylcysteine.....	3	cefuroxime .....	11
<i>acetylsalicylic acid</i> .....	39	charcoal, activated.....	3
aciclovir .....	16, 35	chloramphenicol.....	8
<i>adalimumab</i> .....	22	chlorhexidine.....	30, 36
albendazole .....	5	chlorine base compound .....	30
alcohol based hand rub .....	30	chloroquine .....	19, 20
<i>allopurinol</i> .....	26	chloroxylenol.....	30
<i>all-trans retinoid acid (ATRA)</i> .....	25	<i>chlorpromazine</i> .....	37
amikacin .....	7, 14	cholera vaccine.....	35
amitriptyline .....	2	<i>ciclosporin</i> .....	22
amodiaquine .....	19	ciprofloxacin.....	11, 39
amodiaquine – sulfadoxine + pyrimethamine ...	20	<i>cisplatin</i> .....	22
amoxicillin .....	7	clarithromycin .....	12
amoxicillin + clavulanic acid .....	7, 14	clindamycin.....	8
amphotericin B .....	15, 18	clofazimine .....	14, 15
ampicillin.....	7	cloxacillin .....	9
anti-rabies immunoglobulin .....	28	<i>coagulation factor IX</i> .....	28
anti-tetanus immunoglobulin .....	28	<i>coagulation factor VIII</i> .....	28
anti-venom immunoglobulin .....	33	coal tar.....	30
<i>aprepitant</i> .....	31	colecalfiferol .....	38
<i>arsenic trioxide</i> .....	22	<i>colistin</i> .....	13
artemether .....	19	cyclizine .....	2
artemether + lumefantrine.....	19	<i>cyclophosphamide</i> .....	23
artesunate .....	19	<i>cycloserine</i> .....	15
artesunate + amodiaquine .....	19	<i>cytarabine</i> .....	23
artesunate + mefloquine .....	19	<i>dacarbazine</i> .....	23
artesunate + pyronaridine tetraphosphate.....	19	<i>dactinomycin</i> .....	23
ascorbic acid .....	38	dapsone.....	14
<i>asparaginase</i> .....	22	darunavir.....	17
atazanavir .....	17	<i>dasatinib</i> .....	25
atropine .....	1, 3, 36	<i>daunorubicin</i> .....	23
<i>azathioprine</i> .....	22	<i>deferoxamine</i> .....	4, 28
azithromycin .....	10, 35	<i>delamanid</i> .....	15
<i>barium sulfate</i> .....	30	dengue vaccine.....	35
BCG vaccine .....	34	<i>desmopressin</i> .....	27
<i>bedaquiline</i> .....	15	dexamethasone .....	2, 3, 26, 31
benzathine benzylpenicillin.....	8	dextran 70 .....	29
benznidazole.....	21	diazepam .....	2, 4
benzoyl peroxide.....	30	<i>diazoxide</i> .....	33
benzyl benzoate.....	30	diethylcarbamazine .....	5
benzylpenicillin.....	8	digoxin .....	29
betamethasone.....	29	dihydroartemisinin + piperazine phosphate ..	19
<i>bleomycin</i> .....	22	diloxanide.....	18
budesonide.....	37, 39	<i>dimercaprol</i> .....	4
bupivacaine .....	1	diphtheria antitoxin.....	33
caffeine citrate .....	36	diphtheria vaccine .....	34
calamine .....	29	docusate sodium.....	3
<i>calcium folinate</i> .....	22	dolutegravir.....	17
calcium gluconate.....	3, 39	<i>dopamine</i> .....	29
carbamazepine .....	4	<i>doxorubicin</i> .....	23
<i>carboplatin</i> .....	22	doxycycline .....	9, 20
cefalexin .....	8	efavirenz (EFV or EFZ) .....	17
cefazolin .....	8	eflornithine .....	21
cefixime .....	10	enalapril .....	29
cefotaxime .....	11	enoxaparin .....	27

entecavir.....	18	Japanese encephalitis vaccine.....	34
epinephrine (adrenaline).....	3, 36, 37	ketamine.....	1
erythromycin.....	35	lactulose.....	3
<i>erythropoiesis-stimulating agents</i> .....	27	lamivudine (3TC).....	16
ethambutol.....	14	lamivudine + nevirapine + zidovudine.....	17
ethanol.....	30	lamivudine + zidovudine.....	17
<i>ethionamide</i> .....	15	lamotrigine.....	4
<i>ethosuximide</i> .....	5	levamisole.....	5
<i>etoposide</i> .....	23	<i>levofloxacin</i> .....	15
ferrous salt.....	27	levothyroxine.....	33
fexinidazole.....	21	lidocaine.....	1
<i>filgrastim</i> .....	26	lidocaine + epinephrine (adrenaline).....	1
fluconazole.....	15	<i>linezolid</i> .....	13, 15
flucytosine.....	15	lopinavir + ritonavir (LPV/r).....	17
fludrocortisone.....	32	loratadine.....	3
fluorescein.....	30	lorazepam.....	4
<i>fluorouracil</i> .....	24	<i>Lugol's solution</i> .....	33
fluoxetine.....	3, 37	<i>mannitol</i> .....	31
folic acid.....	27	measles vaccine.....	34
<i>fomepizole</i> .....	4	mebendazole.....	5
<i>fosfomycin</i> .....	13	mefloquine.....	20
fresh–frozen plasma.....	28	<i>melarsoprol</i> .....	21
furosemide.....	29, 31	meningococcal meningitis vaccine.....	35
gentamicin.....	9, 35	<i>mercaptopurine</i> .....	24
glucagon.....	33	<i>meropenem</i> .....	12, 15
glucose.....	38	<i>mesna</i> .....	26
glucose with sodium chloride.....	38	<i>metformin</i> .....	33
glutaral.....	30	<i>methadone</i> .....	2
griseofulvin.....	15	<i>methimazole</i> .....	33
Haemophilus influenzae type b vaccine.....	34	<i>methotrexate</i> .....	24, 39
<i>haloperidol</i> .....	37	<i>methylprednisolone</i> .....	26
halothane.....	1	metoclopramide.....	31
<i>heparin sodium</i> .....	27	metronidazole.....	9, 18
hepatitis A vaccine.....	35	miconazole.....	29
hepatitis B vaccine.....	34	midazolam.....	1, 3, 4
HPV vaccine.....	34	miltefosine.....	18
<i>hydrochlorothiazide</i> .....	31	morphine.....	1, 2
hydrocortisone.....	3, 26, 29, 32	<i>moxifloxacin</i> .....	15
hydroxocobalamin.....	27	multiple micronutrient powder.....	38
<i>hydroxycarbamide</i> .....	24, 28	mumps vaccine.....	35
<i>hydroxychloroquine</i> .....	39	mupirocin.....	29
hyoscine hydrobromide.....	3	naloxone.....	3
ibuprofen.....	2, 21, 36	natamycin.....	35
<i>ifosfamide</i> .....	24	neostigmine.....	35
<i>imatinib</i> .....	25	nevirapine (NVP).....	17
influenza vaccine.....	35	niclosamide.....	5
insulin injection (soluble).....	32	nifurtimox.....	21
intermediate-acting insulin.....	32	<i>nilotinib</i> .....	25
<i>intraperitoneal dialysis solution (of appropriate composition)</i> .....	37	nitrofurantoin.....	9
iodine.....	38	nitrous oxide.....	1
<i>irinotecan</i> .....	24	<i>normal immunoglobulin</i> .....	28
isoflurane.....	1	nystatin.....	16
isoniazid.....	14	ofloxacin.....	36
isoniazid + pyrazinamide + rifampicin.....	14	omeprazole.....	31
isoniazid + pyridoxine + sulfamethoxazole + trimethoprim.....	18	ondansetron.....	3, 31
isoniazid + rifampicin.....	14	oral rehydration salts.....	32, 37
itraconazole.....	16	oral rehydration salts – zinc sulfate.....	32
ivermectin.....	5, 21	<i>oseltamivir</i> .....	18
		<i>oxaliplatin</i> .....	24
		<i>oxamniquine</i> .....	5

oxygen.....	1	ritonavir.....	17
<i>paclitaxel</i> .....	24	<i>rituximab</i> .....	25
<i>p-aminosalicylic acid</i> .....	15	rotavirus vaccine.....	34
<i>pancreatic enzymes</i> .....	31	rubella vaccine.....	34
paracetamol.....	2, 21	salbutamol.....	37
paromomycin.....	18	salicylic acid.....	30
<i>pegaspargase</i> .....	24	senna.....	3
pentamidine.....	21	silver sulfadiazine.....	29
permethrin.....	30	<i>sodium calcium edetate</i> .....	4
pertussis vaccine.....	34	sodium chloride.....	38
phenobarbital.....	4	sodium fluoride.....	39
phenoxymethylpenicillin.....	9	sodium hydrogen carbonate.....	38
phenytoin.....	4	sodium lactate, compound solution.....	38
phytomenadione.....	27	sodium stibogluconate or meglumine antimoniate.....	18
piperacillin + tazobactam.....	12	<i>spironolactone</i> .....	31
platelets.....	28	<i>streptomycin</i> .....	15
pneumococcal vaccine.....	34	<i>succimer</i> .....	4
podophyllum resin.....	30	sulfadiazine.....	20
poliomyelitis vaccine.....	34	sulfadoxine + pyrimethamine.....	20
<i>polymyxin B</i> .....	13	sulfamethoxazole + trimethoprim.....	10, 21
potassium chloride.....	37, 38	suramin sodium.....	21
<i>potassium iodide</i> .....	16, 33	<i>surfactant</i> .....	36
potassium permanganate.....	29	suxamethonium.....	35
povidone iodine.....	30	terbinafine.....	29
praziquantel.....	5	tetanus vaccine.....	34
prednisolone.....	3, 26, 36	tetracaine.....	36
primaquine.....	20	tetracycline.....	36
procaine benzylpenicillin.....	10	thiamine.....	39
<i>procarbazine</i> .....	24	tick-borne encephalitis vaccine.....	35
proguanil.....	20	<i>tioguanine</i> .....	25
propofol.....	1	triclabendazole.....	5
propranolol.....	22	tropicamide.....	30
<i>propylthiouracil</i> .....	33	tuberculin, purified protein derivative (PPD)....	33
<i>prostaglandin E</i> .....	36	typhoid vaccine.....	35
<i>protamine sulfate</i> .....	27	urea.....	30
pyrantel.....	5	<i>valganciclovir</i> .....	18
pyrazinamide.....	14	valproic acid (sodium valproate).....	4, 5
<i>pyridostigmine</i> .....	35	vancomycin.....	12
pyridoxine.....	38	varicella vaccine.....	35
pyrimethamine.....	20	vecuronium.....	35
quinine.....	20	<i>vinblastine</i> .....	25
rabies vaccine.....	35	<i>vincristine</i> .....	25
raltegravir.....	17	voriconazole.....	16
ranitidine.....	31	<i>warfarin</i> .....	27
<i>realgar-Indigo naturalis formulation</i> .....	24	water for injection.....	38
red blood cells.....	28	whole blood.....	28
retinol.....	39	xylometazoline.....	39
ribavirin.....	18	yellow fever vaccine.....	34
riboflavin.....	39	zidovudine (ZDV or AZT).....	16
rifampicin.....	14	zinc sulfate.....	32
rifapentine.....	14		